Animal model for cerebral venous sinus thrombosis using ferric chloride in rabbits
Developing a reliable rabbit model for cerebral venous sinus thrombosis (CVST) using 40% ferric chloride to mimic human disease pathology. This model aids in evaluating drug candidates and anti-thrombotic agents, offering insights into CVST mechanisms and potential treatments.
Overview
This innovative research provides a reliable animal model for studying cerebral venous sinus thrombosis (CVST) by employing 40% ferric chloride (FeCl3) to induce thrombosis in the superior sagittal sinus (SSS) of rabbits. This model closely mimics human CVST pathology, leading to brain infarction, hemorrhage, cell edema, and blood-brain barrier disruption. It serves as a valuable tool for understanding disease mechanisms and testing potential therapeutic interventions.
Technical specifications
- Animal model: Rabbits are used to replicate CVST conditions.
- Induction method: Application of 40% FeCl3 on the superior sagittal sinus.
- Validation procedures: Includes histological analysis, thromboelastography, bleeding time measurement, and high-resolution echocardiography to monitor brain infarctions and assess the efficacy of drug candidates.
- Experimental groups: Control and treatment groups to evaluate the effects of anti-thrombotic agents.
Technology readiness level
The research is at a Technology Readiness Level (TRL) 5, indicating that the concept has been validated in a relevant environment. Further validation and optimization are planned to enhance the model's applicability in drug testing and therapeutic evaluation.
About University of California, San Diego
UC San Diego is a comprehensive public research university in La Jolla, anchored by an integrated academic health system. On the east campus, the 23‑acre Science Research Park co‑locates corporate R&D with university programs and connects to the health sciences district, enabling daily interaction among scientists, clinicians, and companies. The Jacobs School’s Corporate Affiliates Program provides structured engagement and recruiting, while the Office of Innovation & Commercialization supports IP, licensing, and startup formation. The research enterprise is sustained by competitive federal funding, with recent awards exceeding $1.7B annually. Established commercialization pathways streamline sponsored research and help partners move from proof of concept to deployment.
delivered to your inbox.